R63.4 Insurance Policy Changes

ICD-10 R63.4 is officially defined as "Abnormal weight loss." code R63.4 is referenced in 6 tracked payer policy changes from Blue Cross Blue Shield of North Dakota, Aetna, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code R63.4 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Blue Cross Blue Shield of North Dakota · Identified Aug 29, 2026Medium impact
Medical Policy Updates
Blue Cross Blue Shield of North Dakota's August 20, 2026 update covers medical policies its committee reviewed on August 11, 2026. Most changes are reformatting with no change in intent, but several add or remove procedure and diagnosis codes, including the sleep apnea diagnosis list, pediatric sleep apnea equipment codes and cosmetic surgery codes, so billing templates need checking. The notice gives no effective date, and the source says benefit decisions use the policy in effect at the time of service.
Aetna · Identified Aug 17, 2026Medium impact
Helicobacter Pylori Infection Testing (CPB 0177, reviewed 2026-03-20)
Aetna considers FDA-cleared carbon isotope (13C or 14C) urea breath testing and stool antigen testing (HpSA) medically necessary for active Helicobacter pylori infection in selected persons, including adults with idiopathic thrombocytopenic purpura, persons before bariatric surgery, persons before starting proton pump inhibitor therapy for dyspepsia, and persons taking long term, low-dose aspirin or initiating chronic NSAID treatment. Nucleic acid amplification for clarithromycin resistance testing is medically necessary for selecting salvage regimens for treatment-experienced individuals with persistent H. pylori infection. H. pylori serology, the AmHPR panel, IL-1B and TNFA gene polymorphism testing, and urea breath or stool antigen testing for other indications such as stroke risk, dementia risk and screening of asymptomatic persons are considered experimental, investigational or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Celiac Disease Laboratory Testing (CPB 0561, reviewed 2026-08-03)
Serological testing for IgA anti-human tissue transglutaminase (TTG), IgG and IgA deamidated gliadin (DGP), and IgA anti-endomysial (EMA) antibodies is medically necessary as a preliminary diagnostic test for persons with symptoms suggestive of celiac disease, to monitor response to a gluten-free diet, to screen first-degree relatives of individuals with celiac disease, and to screen persons with type 1 diabetes. HLA-DQ2 and HLA-DQ8 genetic testing is medically necessary for listed situations, including seronegative persons with equivocal small bowel histology findings (Marsh I-II), evaluation of persons on a gluten-free diet in whom no serologic testing was performed before starting it, and persons with Down syndrome. Anti-gliadin antibody (AGA) and anti-reticulin antibody (ARA) testing, the Prometheus Celiac Plus Panel, and HLA genotyping for screening persons with type 1 diabetes are experimental, investigational, or unproven.
Aetna · Identified Aug 14, 2026Medium impact
Double Balloon Enteroscopy (CPB 0737, reviewed 2025-11-13)
Aetna considers double balloon enteroscopy medically necessary for dilation of small bowel strictures in Crohn's disease, evaluating suspected small bowel malignancies, evaluating the colon after incomplete colonoscopy, suspected Meckel's diverticulum with an indefinite imaging work-up, obscure GI bleeding with objective evidence of recurrent bleeding, removing entrapped foreign bodies in the small bowel, removing large polyps greater than 10 mm in Peutz-Jeghers syndrome, GI bleeding when the small intestine is the source, and use with ERCP in individuals with surgically altered upper GI anatomy. Aetna considers double balloon enteroscopy experimental, investigational or unproven for other indications, including detection of small bowel neuroendocrine tumors, small bowel varices, treatment of intussusception, treatment of angioectasia (type 1 small bowel vascular lesions), and treatment of post-operative bile leakage after hepaticojejunostomy. Combined double balloon enteroscopy and endoscopic ultrasound for evaluation of Crohn's disease is also considered experimental, investigational or unproven.
Aetna · Identified Aug 13, 2026Medium impact
Pediatric Intensive Feeding Programs (CPB 0809, reviewed 2025-12-11)
Aetna considers professional services for pediatric intensive feeding programs medically necessary for infants and children with complex feeding and swallowing disorders when an interdisciplinary team provides the care and every listed condition is met. Those conditions include behavior problems interfering with feeding, a documented diagnosis-specific treatment plan with estimated length of treatment, medical causes of failure to thrive treated without resolving the feeding problem, physician coordination and oversight, one of the listed feeding problems, and no response to initial treatment by a single discipline over a 2-month period. Other indications, such as childhood obesity and Prader-Willi syndrome, are considered experimental, investigational, or unproven, and electrical stimulation for swallowing or feeding disorders is also considered experimental, investigational, or unproven.
Medical Mutual of Ohio · Identified Jun 20, 2026Medium impact
HEDIS Advanced Illness and Frailty Exclusion
Medical Mutual of Ohio has implemented HEDIS exclusion guidelines for advanced illness and frailty patients. Billing teams must use specific ICD-10 codes to exclude eligible patients (ages 66-80 with both conditions, or 81+ with frailty) from certain HEDIS quality measures like cancer screenings and diabetes management.

Watch R63.4

Get one email when a payer policy names R63.4, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code R63.4?

There are 6 tracked policy changes affecting code R63.4, including updates from Blue Cross Blue Shield of North Dakota, Aetna, Medical Mutual of Ohio. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code R63.4?

Payers that have issued tracked updates for code R63.4 include: Blue Cross Blue Shield of North Dakota, Aetna, Medical Mutual of Ohio.

How do I get notified when code R63.4 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code R63.4. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code R63.4?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Medical Policy Updates

Helicobacter Pylori Infection Testing (CPB 0177, reviewed 2026-03-20)

Celiac Disease Laboratory Testing (CPB 0561, reviewed 2026-08-03)

Double Balloon Enteroscopy (CPB 0737, reviewed 2025-11-13)

Pediatric Intensive Feeding Programs (CPB 0809, reviewed 2025-12-11)

HEDIS Advanced Illness and Frailty Exclusion

What insurance policy changes affect code R63.4?

Which payers have updated policy for code R63.4?

How do I get notified when code R63.4 policy changes?

Why do payers change policies for code R63.4?